CB2 Insights Inc. announces that it has been delayed in filing its annual financial statements (the “Annual Financial Statements”) and associated management discussion and analysis (“MD&A”) for the year-ended December 31, 2019, which were required to be filed on June 15, 2020.
The Company now expects to file the Annual Financial Statements and related MD&A on or before Thursday June 18, 2020.
The delay in filing occurred due to the Company’s auditors request for additional time to finalize its review of the Company’s financial information and to complete its normal audit procedures.
As a result of the above, the Company has rescheduled its earnings call to Friday June 19, 2020 at 9:00 a.m. (EST).
| Conference call details: | |
| DATE: | Friday, June 19, 2020 |
| TIME: | 9:00 a.m. (EST) |
| US/Canada Toll Free Dial In: | 1-800-319-4610 |
| Toronto Local Dial In: | 1-416-915-3239 |
| International Toll: | 1-604-638-5340 |
| CALL NAME: | CB2 Insights Earnings Call |
The Company continues to see strong growth in execution of its business plan. On an unaudited basis, the Company continues to illustrate profitability in Q2 2020. The Company has also strengthened its balance sheet with cash from operations, and the receipt of relief funds available to its US medical services business due to the COVID-19 pandemic.
About CB2 Insights
CB2 Insights CB2 Insights is a healthcare services and technology company, working to positively impact patient health outcomes. Our mission to mainstream alternative health treatments into traditional healthcare by recognizing the need for patient treatment diversity, and the impacts of integrating alternative and conventional medicine. The Company works primarily to roster and treat patients who are seeking alternative treatments due to the ineffectiveness of conventional medicine, and the inability to find support through their existing care network, or in some cases, inability to access a primary care network. Medical services offered by the Company are defined as Integrative medicine, where we work to understand the real world evidence for the safety, impact and effectiveness of medical treatments including plant based medicines that often lack sufficient research and therefore adoption by conventional healthcare providers.
To support patient care and positive health outcomes, the Company is also focused on advancing safety and efficacy research surrounding alternative health treatments by monitoring and assessing Real-World Data (RWD) and providing Real-World Evidence (RWE) through our proprietary technology, data analytics, and a full service contract research organization. .
The Company’s primary operations are in the United States, with application to its insights, technology and research services deployed in other International markets including Canada, United Kingdom and Colombia.
The Company’s disciplined operating model, allows patients to receive access to care in a time efficient and cost-effective manner. Utilizing virtual telehealth and over 31 physical brick and mortar clinics, the Company currently treats over 100,000 patients across 12 States. Utilizing proprietary technology and data analytic platforms, the Company is able to monitor, study and assess a variety of healthcare treatments and products for the safety, efficacy and effectiveness. The Company believes it is well positioned to be the research and technology partner of choice for multiple stakeholders including Big Pharma, Life Sciences, Regulatory Bodies and Payors within the traditional and integrative medical industry.
For more information please visit www.cb2insights.com.
For additional information, please contact:
Investor Relations Department
1.855.847.4999 ext. 212
investors@cb2insights.com
Contact Information:
Investor Relations Department
1.855.847.4999 ext. 212
investors@cb2insights.com
Tags:
, Wire, Disclosure Newswire, United States, English
Contact Information:
Investor Relations Department
1.855.847.4999 ext. 212
investors@cb2insights.com
